Connected Drug Delivery Devices Market – By Device Type, By Technology, By Application, By End Use - Global Forecast, 2025 – 2034

Connected Drug Delivery Devices Market Size

The global connected drug delivery devices market size was valued at around USD 491.2 million in 2024 and is estimated to grow at 31.8% CAGR from 2025 to 2034. Connected drug delivery devices are the combination of medical devices and modern technology involving Bluetooth, Wi-Fi, and the internet of things (IoT) to enhance medication management and administration. These devices, which include smart inhalers, insulin pens, wearable injectors, and intelligent pill boxes, capture and record data on usage of medications, patient adherence, and share information in real time with both patients and healthcare providers.
 

The increasing incidence of chronic diseases like asthma, diabetes, and heart diseases and their significant contributions toward increasing healthcare costs are some of the factors responsible for the progression of this market. For instance, according to the World Health Organization (WHO), about 17.9 million people die every year due to cardiovascular diseases. Connected drug delivery devices stand out in improving medication adherence and effective disease management, thus making them indispensable in alleviating the burden of chronic diseases across the globe. In addition, non-adherence to medication is one of the most challenging issues in healthcare, yielding suboptimal health results and increased costs.
 

For instance, the National Institutes of Health (NIH) reports that poor adherence to medication is estimated to be the cause of 125,000 deaths and 10% of hospitalizations every year. Connected drug delivery devices help resolve this problem by offering real time adherence measurements and automated reminders, which improves treatment results and lessens the financial burden on healthcare systems from nonadherence.
 

Moreover, the U.S. FDA and European Medicines Agency (EMA) are increasingly recognizing and approving connected drug delivery devices which is favorable for a progressive market. For instance, Adherium Limited was granted FDA clearance in April 2024 for its Hailie Smartinhaler to be used with Astra Zeneca’s Airsupra and Breztri inhalation devices. Furthermore, healthcare regulations that target the promotion of digital health solutions are causing a shift towards the acceptance of connected devices, which leaves their integration into the standard of care more likely and improves health outcomes for patients.
 

Connected Drug Delivery Devices Market Trends

• The use of mobile phones and other digital health devices is being extended to connected drug delivery devices for real time performance monitoring, adherence tracking and patient support. This leads to better management of medications as well as compliance, which improves the health of patients and increases the adoption of these devices.
   
• Moreover, the advancement of seamless drug delivery devices is supported by IoT, Bluetooth, and 5G technologies. These improvements increase the compatibility of the devices with Electronic Health Records (EHRs) and telehealth services.
   
• For instance, the U.S. Centers for Disease Control and Prevention (CDC) reported that in 2021, 88.2% of office-based physicians used EHR systems, creating a favorable environment for integration for smart drug delivery systems. The widespread use of EHR systems allows for the integration of smart devices into the healthcare systems with minimal effort.
   
• Also, the growing regulatory approvals of connected drug delivery systems is changing market dynamics. The U.S. FDA and EMA regulatory bodies are offering less resistance for technologies in the digital health space.
   
• Since 2020, the FDA Digital Health Center of Excellence has boosted approval rates for forward-thinking innovations which has increased provider trust in the industry. In October 2021, the Canadian company BreatheSuite, specializing in respiratory health, received 510(k) clearance from the FDA for the BreatheSuite Metered-Dose Inhaler (MDI) V1 device. This rise supports the adoption of connected devices and driving innovation through regulation.
   

Connected Drug Delivery Devices Market Analysis

Based on device type, the market is bifurcated into connected sensors and integrated devices. The market was valued at USD 408.8 million in 2023. The integrated devices segment dominated the market with the largest revenue share of 60.9% in 2024.

• Integrated devices with reminders, tracking features, and data sharing capabilities can enable patients to adhere to their treatment plans. With these devices, healthcare professionals could monitor medication and health data usage in a remote healthcare setting, which improved treatment outcomes and subsequently increased the use of integrated devices.
   
• Moreover, the rising prevalence of diabetes, asthma, and cardiovascular diseases is also fueling the market for integrated drug delivery devices.
   
• For instance, the WHO reported that in 2022, 14% of adults aged 18 and older were diabetic compared to 7% in 1990, which underscores the need for effective drug delivery systems. These devices ensure compliance with medication and provide effective management of long-term diseases, thereby dealing with the increasing burden of chronic diseases globally.
   
• Further, the integration of IoT, AI, and mobile applications into drug delivery devices allow for monitoring, dose tracking, and personalized care in real time. These features advance the treatment results as well as patient adherence to treatment, therefore, encourage the growth of the segment.
   

Based on technology, the connected drug delivery devices market is segmented into Bluetooth, near field communication, and Wi-Fi. The Bluetooth segment dominated the market with the largest revenue share of 47.7% in 2024.
 

• Low power usage alongside cost-efficient systems and easy adoption in mobile health (mHealth) applications is aiding the domination of the segment. Real-time data exchange for remote monitoring and medication adherence between patients, healthcare providers, and digital health platforms is possible through Bluetooth-enabled devices.
   
• In addition, rising instances of chronic diseases are increasing demand for Bluetooth-enabled smart inhalers, smart insulin pens, and autoinjectors. For instance, Teva Pharmaceuticals’ ProAir Digihaler and AirDuo Digihaler, track inhaler usage and communicate the data to a mobile application, thereby increasing patient compliance.
   
• Moreover, this segment’s leadership is being augmented by investment from pharmaceutical and MedTech companies in Bluetooth-enabled biosensors and wearable injectors.
   

Based on application, the connected drug delivery devices market is segmented into anaphylaxis, respiratory, cardiovascular, diabetes, hormone replacement, and other applications. The respiratory segment dominated the market with the largest revenue of USD 221 million in 2024.
 

• The increase in the global burden of asthma and chronic obstructive pulmonary disease (COPD) and other respiratory disorders increases the need for connected delivery devices that can help in better management of respiratory diseases.
   
• For instance, the American Lung Association reported in 2022 that 44.2 million individuals in the U.S. had been diagnosed with asthma, a staggering 48% rise from 9.1% in 1999. This immense burden of these diseases underscores the need for effective solutions in drug delivery and respiratory treatment management.
   
• Additionally, these devices also aid remote monitoring of patients, supporting in the expansion of telehealth services and continuous care for patients suffering from respiratory issues. During the pandemic of COVID-19, these devices were shown to be exceedingly helpful which drove their adoption across various healthcare environments and thus increased their revenue.
   

Based on end use, the connected drug delivery devices market is segmented into hospitals, clinics, home care settings, and other end users. The home care settings segment dominated the market with the largest revenue of USD 198.5 million in 2024.
 

• The growing preference for home care, is due to a rise in the aging population globally as well as increasing emphasis on chronic disease management. Thus, as there is demand for connected drug delivery systems that support self-administration and monitoring, this segment is expected to grow in the near future.
   
• For instance, an analysis performed by National Council on Aging in 2022 revealed that 95% of adults aged above 60 had at least one chronic ailment and two thirds of that population had two or more. Such statistics highlight the need for effective home healthcare systems. Moreover, connected drug delivery devices in home care let elderly people lead an independent life, further fostering expansion of this segment.
   
• Additionally, connected devices also aid in expansion of telehealth services by enabling healthcare professionals to monitor patients remotely and provide proper treatment without the requirement of patients to visit the hospitals.
   

North America: The U.S. connected drug delivery devices market is projected to grow significantly, from USD 156 million in 2023 to USD 2.7 billion by 2034.
 

• The country faces an increase in telehealth services, especially after the onset of the COVID-19 pandemic, which has boosted the use of connected devices for remote monitoring and healthcare services.
   
• For instance, telehealth visits surged 154% for the last week of March 2020 compared to the same week in 2019, showing how fast the industry is moving towards digitization. The need for connected drug delivery devices has been augmented due to this surge in telehealth in the country.
   
• In addition, the U.S. FDA promotes innovation in digital health technology via its Digital Health Center of Excellence which accelerates the approval of connected drug delivery devices and fosters their adoption in the market.
   
• For instance, the FDA's official record showed that 91 medical devices and algorithms that incorporate AI/ML were authorized in 2022. Moreover, consistent regulatory support has established a positive and stable atmosphere for the commercialization of these products.
   

Europe: The UK connected drug delivery devices market is expected to experience significant and promising growth from 2025 to 2034.
 

• The increasing prevalence of chronic diseases in the UK has led to an increase in the need for connected drug delivery devices, which enhance medication adherence and patient outcomes. Diabetes UK has estimated that in 2023, about 5.8 million people in the UK were living with diabetes. Moreover, there are also estimates that about 1.3 million people were suffering from undiagnosed type two diabetes. This emerging patient population needs better solutions to drug delivery systems for adequate disease management.
   
• In addition, the Medicines and Healthcare Products Regulatory Agency (MHRA) has created efficient approval processes for the connected medical devices, which enables the expansion of the market in the UK.
   
• For instance, in January 2024, the MHRA published a roadmap for new regulations on medical devices, and updated the post-market surveillance requirements through The Medical Devices (Post-market Surveillance Requirements) Regulations 2024. The objectives are to increase the UK’s stature as a leader in medical technology and to enable the country to meet most international standards.
   

Asia Pacific: Japan connected drug delivery devices market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan experiences a rapidly aging population which is anticipated to increase the prevalence of chronic diseases, including diabetes and respiratory conditions. For instance, according to the Japanese Ministry of Internal Affairs and Communications, the number of individuals aged 80 or older increased by 270,000 from 2022, reaching a record 12.5 million, which is 10% of Japan's population. This demographic shift strengthens the need for connected drug delivery devices that enable home care and self-management, particularly for elderly patients managing multiple conditions.
   
• Moreover, the advanced technologies in the country allow innovative connected drug delivery devices to have additional features such as data analysis, remote monitoring, and easy to use interface.
   

Middle East and Africa: Saudi Arabia connected drug delivery devices market is expected to experience significant and promising growth from 2025 to 2034.
 

• The growing rates of chronic conditions such as diabetes and heart diseases in Saudi Arabia worsens the concern and hence increases the need for the connected drug delivery devices to aid in medical compliance and illness management. For example, research from the National Institute of Health claim that CVD is one of the leading causes of mortality in Saudi Arabia, causing more than 45% of all deaths. This phenomenon shows the existing burden of disease in the region and makes it necessary to have better drug delivery systems.
   
• Furthermore, Saudi Food and Drug Authority (SFDA) is revising regulatory frameworks and the approval process for solutions in digital health, which is expected to accelerate the creation and adoption of new connected drug delivery devices.
   

Connected Drug Delivery Devices Market Share

The market is competitive and includes big global players as well as a wide array of emerging companies. Phillips-Medisize, Teva Pharmaceuticals, Propeller Health, Ypsomed, and Aptar Pharma comprise the top five companies in this sector. Together, these companies contributed around 50% of the revenues. Advanced connected drug delivery devices like smart inhalers, wearable medical devices, mobile health applications, automated dosing systems, and IoT connected drug delivery systems have been the focus of spending for most competitors in the market.
 

In addition, they are also developing AI-powered medication adherence products to diversify their offerings. For instance, Aptar Pharma Connected Devices Platform improves patient engagement by tracking and reminding patients of doses in real time for multiple drug forms. Additionally, wearable drug delivery devices and AI-powered patient adherence devices by new entrants are also intensifying competition and market growth.
 

Connected Drug Delivery Devices Market Companies

Some of the eminent market participants operating in the connected drug delivery devices industry include:

• Adherium
• Aptar Pharma
• AstraZeneca
• Becton, Dickinson, and Company
• Bigfoot Biomedical
• Cohero Health
• Eli Lilly and Company
• Insulet Corporation
• Novartis
• Novo Nordisk
• Phillips Medisize
• Propeller Health
• Teva Pharmaceuticals
• West Pharmaceutical Services
• Ypsomed
   
• Phillips-Medisize focuses on developing fully integrated drug delivery solutions with wireless connectivity, smart sensors, and mobile application integration that facilitates medication adherence. For instance, the Smart Autoinjector Platform automates the reporting of doses taken and captured patient reported outcomes, thus helping to improve the management of chronic diseases.
   
• Propeller Health is one of the leading players in the fusion of Bluetooth powered sensors with asthma and COPD medications to develop smart inhalers. Physician monitoring is supported with the clinical data from the Propeller Platform that includes medicine adherence sensors, a web portal or mobile app, and tailored clinical support and coaching. The company collaborates with large pharmaceutical companies to broaden their scope of business.
   
• Teva Pharmaceuticals is a global player with strong distribution and has introduced ProAir Digihaler and AirDuo Digihaler, which are both FDA-approved smart inhalers. These inhalers capture and wirelessly transmit usage information to mobile devices. Such product innovations enhance patient adherence and physician supervision, hence fortifying Teva's market share.
   

Connected Drug Delivery Devices Industry News:

• In January 2020, Aptar Pharma announced its partnership with Lupin Limited to launch India's first connected device for metered-dose inhalers (MDI) called ADHERO. This innovative add-on smart device was designed to assist patients with chronic respiratory diseases in tracking their MDI usage and improving adherence to their prescribed therapy. This launch enhanced Aptar Pharma's portfolio and strengthened its position in the growing connected drug delivery market, ultimately contributing to better patient outcomes.
   
• In May 2020, Propeller Health announced that it received 510(k) clearance from the U.S. FDA to connect patients using the Symbicort Inhaler to its digital health platform. This approval allowed Propeller Health to expand its offerings, enhance patient engagement, and improve health outcomes for individuals managing respiratory conditions.
   

The connected drug delivery devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• Connected sensors
  • Connected inhalation sensors
  • Connected injectable sensors
• Integrated devices
  • Integrated inhalation devices
  • Integrated injectable devices

Market, By Technology

• Bluetooth
• Near field communication
• Wi-Fi

Market, By Application

• Anaphylaxis
• Respiratory
• Cardiovascular
• Diabetes
• Hormone replacement
• Other applications

Market, By End Use

• Hospitals
• Clinics
• Home care settings
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Poland
  • Switzerland
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
  • Indonesia
  • Vietnam
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Columbia
  • Peru
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Israel